FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W60055175> ?p ?o ?g. }

• W60055175 endingPage "508" @default.
• W60055175 startingPage "495" @default.
• W60055175 abstract "A total of 68 adult patients with B-cell acute lymphoblastic leukemia (B-ALL) were treated in three consecutive adult multicenter ALL studies. The diagnosis of B-ALL was confirmed by L3 morphology and/or by surface immunoglobulin (Slg) expression with > 25% blast cell infiltration in the bone marrow (BM). They were characterized by male predominance (78%) and a median age of 34 years (15 to 65 y) with only 9% adolescents (15 to 20 y), but 28% elderly patients (50 to 65 y). The patients received either a conventional (N = 9) ALL treatment regimen (ALL study 01/81) or protocols adapted from childhood B-ALL with six short, intensive 5-day cycles, alternately A and B. In study B-NHL83 (N = 24) cycle A consisted of fractionated doses of cyclophosphamide 200 mg/m2 for 5 days, intermediate-dose methotrexate (IdM) 500 mg/m2 (24 hours), in addition to cytarabine (AraC), teniposide (VM26) and prednisone. Cycle B was similar except that AraC and VM26 were replaced by doxorubicin. Major changes in study B-NHL86 (N = 35) were replacement of cyclophosphamide by ifosphamide 800 mg/m2 for 5 days, an increase of IdM to high-dose, 1,500 mg/m2 (HdM) and the addition of vincristine. A cytoreductive pretreatment with cyclophosphamide 200 mg/m2, and prednisone 60 mg/m2, each for 5 days was recommended in study B-NHL83 for patients with high white blood cell (WBC) count (e 2,500/m2) or large tumor burden and was obligatory for all patients in study B-NHL86. Central nervous system (CNS) prophylaxis/treatment consisted of intrathecal methotrexate (MTX) therapy, later extended to the triple combination of MTX, AraC, and dexamethasone, and a CNS irradiation (24 Gy) after the second cycle. Compared with the ALL 01/81 study where all the patients died, results obtained with the pediatric protocols B-NHL83 and B-NHL86 were greatly improved. The complete remission (CR) rates increased from 44% to 63% and 74%, the probability of leukemia free survival (LFS) from 0% to 50% and 71% (P = .04), and the overall survival rates from 0% to 49% and 51% (P = .001). Toxicity, mostly hematotoxicity and mucositis, was severe but manageable. In both studies B-NHL83 and B-NHL86, almost all relapses occurred within 1 year. The time to relapse was different for BM, 92 days, and for isolated CNS and combined BM and CNS relapses, 190 days (P = .08). The overall CNS relapses changed from 50% to 57% and 17%, most probably attributable to the high-dose MTX and the triple intrathecal therapy. LFS in studies B-NHL83 and B-NHL86 was significantly influenced by the initial WBC count < or > 50,000/microL, LFS 71% versus 29% (P = .003) and hemoglobin value > or < 8 g/dL, LFS 67% versus 27% (P = .02). Initial CNS involvement had no adverse impact on the outcome. Elderly B- ALL patients (> 50 years) also benefited from this treatment with a CR rate of 56% and a LFS of 56%. It is concluded that this short intensive therapy with six cycles is effective in adult B-ALL. HdM and fractionated higher doses of cyclophosphamide or ifosphamide seem the two major components of treatment." @default.
• W60055175 created "2016-06-24" @default.
• W60055175 creator A5004330294 @default.
• W60055175 creator A5005594026 @default.
• W60055175 creator A5007344745 @default.
• W60055175 creator A5008866380 @default.
• W60055175 creator A5013939045 @default.
• W60055175 creator A5028673634 @default.
• W60055175 creator A5033935778 @default.
• W60055175 creator A5042935151 @default.
• W60055175 creator A5049585376 @default.
• W60055175 creator A5052980484 @default.
• W60055175 creator A5058443791 @default.
• W60055175 creator A5059838325 @default.
• W60055175 creator A5061020169 @default.
• W60055175 creator A5061869444 @default.
• W60055175 creator A5062688084 @default.
• W60055175 creator A5066213019 @default.
• W60055175 creator A5070237578 @default.
• W60055175 creator A5073421855 @default.
• W60055175 creator A5073667628 @default.
• W60055175 creator A5074633455 @default.
• W60055175 creator A5078376583 @default.
• W60055175 creator A5084457753 @default.
• W60055175 creator A5090985755 @default.
• W60055175 creator A5091014964 @default.
• W60055175 creator A5091537377 @default.
• W60055175 date "1996-01-15" @default.
• W60055175 modified "2023-10-16" @default.
• W60055175 title "Improved outcome in adult B-cell acute lymphoblastic leukemia" @default.
• W60055175 cites W124072189 @default.
• W60055175 cites W1243984806 @default.
• W60055175 cites W13968 @default.
• W60055175 cites W1491154431 @default.
• W60055175 cites W1582130462 @default.
• W60055175 cites W158940948 @default.
• W60055175 cites W177753754 @default.
• W60055175 cites W1814753114 @default.
• W60055175 cites W1832431868 @default.
• W60055175 cites W1850094271 @default.
• W60055175 cites W1979300931 @default.
• W60055175 cites W1982149777 @default.
• W60055175 cites W1983233287 @default.
• W60055175 cites W1989937920 @default.
• W60055175 cites W1990318898 @default.
• W60055175 cites W1999635713 @default.
• W60055175 cites W2011647232 @default.
• W60055175 cites W2021452838 @default.
• W60055175 cites W2033190113 @default.
• W60055175 cites W2040893788 @default.
• W60055175 cites W2047494832 @default.
• W60055175 cites W2052218911 @default.
• W60055175 cites W2063826350 @default.
• W60055175 cites W2069455563 @default.
• W60055175 cites W2076426515 @default.
• W60055175 cites W2139984188 @default.
• W60055175 cites W2163251241 @default.
• W60055175 cites W2178439187 @default.
• W60055175 cites W2211691998 @default.
• W60055175 cites W2236985539 @default.
• W60055175 cites W2269250750 @default.
• W60055175 cites W2278728288 @default.
• W60055175 cites W2332960052 @default.
• W60055175 cites W2336990540 @default.
• W60055175 cites W2398910750 @default.
• W60055175 cites W2402696031 @default.
• W60055175 cites W2402802888 @default.
• W60055175 cites W2409312248 @default.
• W60055175 cites W2411460164 @default.
• W60055175 cites W2411923457 @default.
• W60055175 cites W2416270223 @default.
• W60055175 cites W2417396511 @default.
• W60055175 cites W2467334241 @default.
• W60055175 cites W328988336 @default.
• W60055175 cites W346470048 @default.
• W60055175 cites W86273376 @default.
• W60055175 doi "https://doi.org/10.1182/blood.v87.2.495.bloodjournal872495" @default.
• W60055175 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8555471" @default.
• W60055175 hasPublicationYear "1996" @default.
• W60055175 type Work @default.
• W60055175 sameAs 60055175 @default.
• W60055175 citedByCount "297" @default.
• W60055175 countsByYear W600551752012 @default.
• W60055175 countsByYear W600551752013 @default.
• W60055175 countsByYear W600551752014 @default.
• W60055175 countsByYear W600551752015 @default.
• W60055175 countsByYear W600551752016 @default.
• W60055175 countsByYear W600551752017 @default.
• W60055175 countsByYear W600551752018 @default.
• W60055175 countsByYear W600551752020 @default.
• W60055175 countsByYear W600551752021 @default.
• W60055175 countsByYear W600551752022 @default.
• W60055175 crossrefType "journal-article" @default.
• W60055175 hasAuthorship W60055175A5004330294 @default.
• W60055175 hasAuthorship W60055175A5005594026 @default.
• W60055175 hasAuthorship W60055175A5007344745 @default.
• W60055175 hasAuthorship W60055175A5008866380 @default.
• W60055175 hasAuthorship W60055175A5013939045 @default.

• next